Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
2026-10-10. The following slide deck was published by Kodiak Sciences Inc.
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that clinical data across all three of its late-stage assets—Zenkuda (tarcocimab tedromer), tabirafusp-ted (KSI-501) and KSI-101— will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2026).
Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.
Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.
Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.
The biotech is developing innovative therapies for people with eye diseases.
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.
Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]
Kodiak Sciences Inc. stock jumps 140% on Phase 3 DAYBREAK wet AMD results. Click for this updated look at KOD and see if it belongs in your portfolio.
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated...
Here are some of the companies making headlines in midday trading.
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.
Key TakeawaysKodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
Nvidia launches the largest-ever U.S. stock buyback.
Kodiak Sciences shares saw their biggest ever single-day gains after the company posted positive Phase 3 data for 2 therapies targeting wet age-related macular degeneration.
Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.
This is the newest page. Registered accounts read further back.